Is Maraviroc safe while breastfeeding?
Here is what NIH LactMed, the U.S. National Library of Medicine's authority on medicines and breastfeeding, reports about Maraviroc. This is a summary of that source — not our own verdict.
Effects on the breastfed infant
A woman with HIV was treated with maraviroc 150 mg twice daily, lamivudine 150mg twice daily and lopinavir 400 mg plus ritonavir 100 mg twice daily. Her infant received zidovudine 4 mg/kg twice daily for 14 days at birth and was exclusively breastfed until 6 months of age, then partially breastfed until 7 months of age. Clinical and laboratory assessment at 2, 4, and 8 weeks, and 3, 6, 9, and 12 months after birth showed normal development. Full blood cell count, renal, and liver parameters remained within normal range. HIV-DNA PCR results were consistently negative, and at 12 months of age, an HIV antibody test was negative.[ 3 ]
Effects on milk supply
Gynecomastia has been reported among men receiving highly active antiretroviral therapy. Gynecomastia is unilateral initially, but progresses to bilateral in about half of cases. No alterations in serum prolactin were noted and spontaneous resolution usually occurred within one year, even with continuation of the regimen.[ 4 - 6 ] Some case reports and in vitro studies have suggested that protease inhibitors might cause hyperprolactinemia and galactorrhea in some male patients,[ 7 , 8 ] although this has been disputed.[ 9 ] The relevance of these findings to nursing mothers is not known. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
Levels in milk
Maternal Levels. A woman with HIV was treated with maraviroc 150 mg twice daily, lamivudine 150 mg twice daily and lopinavir 400 mg plus ritonavir 100 mg twice daily. She exclusively breastfed her infant until 6 months of age, then partially breastfed her infant until 7 months of age. At 5 months postpartum, paired maternal milk and plasma samples were obtained before a dose and at 1, 2, 4, 6, 8, and 12 hours after a dose of maraviroc. A peak milk level of 415 mcg/L occurred 2 hours after the dose. The level was almost as high at 4 hours, and then fell to less than 100 mcg/L at 12 hours after the dose. The average milk concentration was 193 mcg/L, which yields a daily infant dose of 29 mcg/kg of maraviroc. Assuming a maternal weight of 60 kg, this translates to a weight-adjusted infant dosage of 0.6%.[ 3 ] Infant Levels. A woman with HIV was treated with maraviroc 150 mg twice daily, lamivudine 150mg twice daily and lopinavir 400 mg plus ritonavir 100 mg twice daily. At 5.5 months of age, a single plasma sample was obtained (time with respect to dose and nursing not stated) from the infant during exclusive breastfeeding. Maraviroc was undetectable ( 2.5 mcg/L) in the infant s plasma.[ 3 ]
Source: NIH LactMed (National Library of Medicine).
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.